Not sure if this has been posted already or not, but drug company MSD recently acquired a medical drug company EyeBio which develops a drug to treat DME (diabetic macular oedema). 1.3 Bn USD upfront and up to addtional 1.7 Bn USD in milestone payments.
https://www.msd.com/news/msd-to-acquire-eyebio/
This seems the same field (disease) that 2RT is currently authorized in Europe (if I am not mistaken): https://simovision.com/assets/Uploads/Brochure-Ellex-2RT-EN.pdf
Seems like a positive event, which I think signifies how undervalued NovaEye is - not only in the iTrack front, but also in the 2RT side which seems to get no valuation at all.
EYE Summary (August 2024): Incredibly Undervalued, page-374
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.0¢ | $24.11K | 132.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 137086 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 14.41pm 04/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |